quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Once-in-a-Decade Opportunity: 1 AI Software Stock to Buy While It's Still Down

View original at nasdaq.com
Once-in-a-Decade Opportunity: 1 AI Software Stock to Buy While It's Still Down Key Points Salesforce's AI business is scaling rapidly, with Agentforce reaching annual recurring revenue of $800 million…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • All the top 10 deals secured by Salesforce in the fourth quarter included Agentforce

    60% confidence

  • More than 60% of Agentforce and Data 360 bookings were from existing customers

    60% confidence

  • The 10 best stocks for investors to buy now do not include Salesforce

    60% confidence

  • Stock Advisor's total average return is 898%, compared to 183% for the S&P 500

    60% confidence

  • Salesforce stock seems like a smart buy now considering its relatively modest valuation alongside improving AI-powered growth indicators

    60% confidence

  • Salesforce expects organic subscription and support revenue growth to reaccelerate in the second half of fiscal 2027

    60% confidence

Data points we hold from this source

Salesforce · remaining performance obligations72.4 USD
Salesforce · current rpo growth16 percent
Salesforce · current rpo35.1 USD
Salesforce · agentforce data360 arr growth200 percent
Salesforce · agentforce data360 combined arr2.9 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Once-in-a-Decade Opportunity: 1 AI Software Stock to Buy While It's Still Down — Source | Via News | pt.VIA.NEWS